Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Bonum Therapeutics is raising $93,041,420.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Mulligan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bonum Therapeutics
Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

To learn more about Bonum Therapeutics, visit http://bonumtx.com/

Contact:
John Mulligan, Chief Executive Officer
206-888-8485
https://www.linkedin.com/in/john-mulligan-ph-d-5aa5a37/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved